Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Cytek Biosciences, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
08/21/2023 144 Form 144 - Report of proposed sale of securities:
08/14/2023 144 Form 144 - Report of proposed sale of securities:
08/08/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/08/2023 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Cytek Biosciences Reports Second Quarter 2023 Financial Results"
07/24/2023 144 Form 144 - Report of proposed sale of securities:
06/07/2023 144 Form 144 - Report of proposed sale of securities:
05/15/2023 144 Form 144 - Report of proposed sale of securities:
05/09/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/09/2023 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Cytek Biosciences Reports First Quarter 2023 Financial Results"
05/08/2023 144 Form 144 - Report of proposed sale of securities:
05/05/2023 SC 13G/A BlackRock Inc. reports a 10.9% stake in Cytek Biosciences
04/24/2023 144 Form 144 - Report of proposed sale of securities:
04/19/2023 144 Form 144 - Report of proposed sale of securities:
03/24/2023 144 Form 144 - Report of proposed sale of securities:
03/20/2023 144 Form 144 - Report of proposed sale of securities:
03/01/2023 10-K Annual Report for the period ended December 31, 2022
02/28/2023 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Cytek Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results"
02/28/2023 8-K Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
02/14/2023 SC 13G/A HHLR ADVISORS, LTD. reports a 6.4% stake in Cytek Biosciences, Inc.
02/13/2023 8-K Quarterly results
02/09/2023 SC 13G VANGUARD GROUP INC reports a 5.8% stake in Cytek Biosciences Inc.
02/03/2023 SC 13G BlackRock Inc. reports a 6.2% stake in Cytek Biosciences
11/09/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/09/2022 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Cytek Biosciences Reports Third Quarter 2022 Financial Results"
08/26/2022 S-3ASR Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers:
08/10/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/10/2022 8-K Quarterly results
08/03/2022 SC 13G/A 3E Bioventures Capital, L.P. reports a 4.2% stake in Cytek Biosciences, Inc.
06/06/2022 8-K Quarterly results
05/11/2022 10-Q Quarterly Report for the period ended March 31, 2022
05/11/2022 8-K Quarterly results
04/14/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/14/2022 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/17/2022 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy